中国组织工程研究

中国组织工程研究 ›› 2011, Vol. 15 ›› Issue (18): 3298-3301.doi: 10.3969/j.issn.1673-8225.2011.18.017

• 移植与免疫 transplantation and Immunology • 上一篇    下一篇

Genistein联合小剂量他克莫司在胰腺移植排斥反应中的作用

周  健，朱新国，陈  彦，李德春   

  1. 苏州大学附属第一医院普外科，江苏省苏州市  215006
  • 收稿日期:2011-03-17 修回日期:2011-04-03 出版日期:2011-04-30 发布日期:2011-04-30
  • 通讯作者: 李德春，主任医师，教授，博士生导师，苏州大学附属第一医院普外科，江苏省苏州市 215006
  • 作者简介:周健☆，男，1976年生，江苏省苏州市人，汉族，苏州大学在读博士，主治医师，主要从事胰腺疾病的基础和临床研究。 zj0612@163. com
  • 基金资助:

    苏州市科教兴卫项目(8WKQ0802)。

Roles of Genistein combined with subtherapeutic FK506 in the rejection of pancreas transplantation

Zhou Jian, Zhu Xin-guo, Chen Yan, Li De-chun   

  1. Department of General Surgery, the First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu Province, China
  • Received:2011-03-17 Revised:2011-04-03 Online:2011-04-30 Published:2011-04-30
  • Contact: Li De-chun, Chief physician, Professor, Doctoral supervisor, Department of General Surgery, the First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu Province, China
  • About author:Zhou Jian☆, Studying for doctorate, Attending physician, Department of General Surgery, the First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu Province, China zj0612@163.com
  • Supported by:

    Health Science and Education Program of Suzhou City, No. 8WKQ0802*

PDF

291

摘要：

背景：有实验表明CXCR3拮抗剂Genistein可减轻胰腺移植大鼠的急性排斥反应。
目的：观察Genistein联合小剂量他克莫司在胰腺移植抗排斥反应中的作用。
方法：以Wistar大鼠为供体，SD大鼠为受体，建立胰腺移植模型，随机分成5组：对照组(未进行药物治疗)、大剂量他克莫司组、小剂量他克莫司组、Genistein组、Genistein+小剂量他克莫司组。术后第7天行病理学，肝肾功能，血清中CD3+、CD4+、CD8+T淋巴细胞、干扰素γ、白细胞介素2浓度检测。
结果与结论：与对照组、小剂量他克莫司组、Genistein组比较，Genistein+小剂量他克莫司组移植胰腺组织损伤减轻，淋巴细胞浸润减少，急性排斥反应减轻，血清CD3+、CD4+、CD8+ T淋巴细胞明显减少，干扰素γ、白细胞介素2水平降低(P < 0.05)；并且避免了大剂量他克莫司对肝肾功能的损害。说明Genistein联合小剂量他克莫司能有效减轻胰腺移植急性排斥反应而不增加肝肾毒性。

关键词: 胰腺移植, CXCR3, Genistein, 他克莫司, 干扰素&gamma, 白细胞介素2

Abstract:

BACKGROUND: It has been demonstrated that CXCR3-inhibitor Genistein can mitigate the acute rejection of pancreas transplantation efficiently, but the effect of Genistein and FK506 has not been illustrated.
OBJECTIVE: To investigate the role of CXCR3-inhibitor Genistein combined with subtherapeutic FK506 in the rejection of pancreas transplantation. 
METHODS: Five groups of rats underwent pancreas transplantation: the groups were untreated group; large-dose FK506 group; small-dose FK506 group; Genistein group; and Genistein+small-dose FK506 group. The grafts of three groups were harvested at day 7 after operation for histopathology. The expressions of CD3+, CD4+, CD8+T cells in peripheral blood were assessed by FCM, and the levels of interferon gamma (IFN-γ) and interleukin 2 (IL-2) in serum were examined by ELISA. 
RESULTS AND CONCLUSION: The damage of graft tissue in Genistein+small-dose FK506 group significantly alleviated and the infiltration of lymphocytes decreased as compared with untreated group, small-dose FK506 group and Genistein group . It proved that the Genistein+small-dose FK506 combination-therapy could prevent the acute rejection. Genistein+small-dose FK506 combination therapy decreased the dosage of FK506 and prevented the damage effect on the recipients’ hepatic and renal functions. The number of CD3+, CD4+, CD8+ T cells in Genistein+small-dose FK506 group were much less; in addition, down-regulation of IFN-γ, IL-2 in serum were observed in Genistein+small-dose FK506 group. It was demonstrated that CXCR3-inhibitor Genistein combined with  subtherapeutic FK506 could mitigate the acute rejection of pancreas transplantation efficiently and not increase hepatic and renal toxicity.

中图分类号: